Be part of it

Redefining Cancer Monitoring. Join the movement.

Return on Invest

Where immunotherapy advances, opportunity follows

Patients:

= 100.000.000 patients
80 % or 800.000 are
non-responders

Costs:

€5-6k per infusion every 3 weeks
€8k per month
per patient

Time to assessment:

Currently: 12+ weeks
imuveo: 4 weeks

Savings:

Per patient: €16k
Total: €12.8 Bn each year

Identifying non-responders early would save about  €12.8 billion every year for healthcare systems.

Infrastructure

Innovation that runs on a wast and expanding ecosystem.

Nuclear medicine is entering a new era. Around the world, hospitals and research centers are rapidly expanding their PET imaging capabilities, driven by the growing demand for precision diagnostics and theranostics. Concretely, this means:

No New Equipment Needed – Fully compatible with existing 68Ga-Generators and PET scanners.
Easy Integration – Fits seamlessly into current hospital radiopharmacy workflows.
Scalable from Day One – Ready for use across university hospitals and imaging centers.
Cost-Efficient Rollout – Leverages infrastructure already in place, minimizing barriers to adoption.
Daily Use Enabled – Designed for routine clinical application, not just research settings.

We will integrate into the existing & well-established ecosystem, which will even grow.

Outlook

Our pipeline of novel
PET tracers

Driving the Future of Precision Oncology

imuveo is advancing on multiple fronts to transform how our technology can impact patients lifes. Our lead asset - the CD2-targeted single-domain antibody, is on the verge of entering a Phase I trial, marking a major milestone in for imuveo and immunotherapy monitoring. At the same time, we are expanding our pipeline to explore novel approaches in cancer treatment and beyond, aiming to bring precision diagnostics and therapies to other immune-driven diseases.

Support us

Unlock the power of T-cell imaging - whether you're investing or innovating.

Shape the future of immunotherapy - join us in setting a new standard and backing our Phase 1 trial, as partner or investor.

learn more

The ecosystem is established and key players see the potential.
Every step along the way adds value to our project – and increases your ROI.
Boost your preclinical pipeline -add value to your biotech or pharma projects with precise T-cell tracking.